Morgan Stanley affirms Sino Biopharmaceutical Limited's (01177.HK) acquisition of the remaining 95.09% stake in LaNova Medicine for US$501 million as reasonably priced. This follows Sino Biopharm's earlier investment of RMB142 million for a 4.91% ownership. The transaction valuation reflects LaNova's promising late-stage pipelines and two completed out-licensing agreements. This strategic move grants Sino Biopharm access to multiple technological platforms, significantly strengthening its oncology portfolio. Morgan Stanley reiterates its "Overweight" rating with a HK$4.9 target price, anticipating enhanced tumor pipeline development through this acquisition.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。